CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Apr. 30, 2025	Apr. 30, 2024
Income Statement [Abstract]
Revenue	$ 0	$ 0
Operating expenses:
Research and development costs	438,416	407,431
Intangible asset impairment	0	2,000,000
General and administrative	3,939,446	6,112,577
Total operating expenses	4,377,862	8,520,008
Loss from operations	(4,377,862)	(8,520,008)
Other income (expense):
Interest income	1,415,561	3,398,819
Change in fair value of warrant liability	10,446,000	3,343,000
Change in fair value of derivative liability	2,184,000	586,000
Change in fair value of convertible note receivable – Femasys	941,000	1,089,000
Change in fair value of warrant asset – Femasys	(2,091,000)	1,818,000
Change in fair value of investment – TNF	5,063,950	0
Change in fair value of warrant assets - TNF	(2,367,684)	0
Gain on investment in preferred stock – TNF	21,395,734	0
Unrealized gain on marketable securities	66,316	0
Loss on legal settlement	(2,019,000)	0
Loss on long term asset	0	(1,572,193)
Other income (expense), net	(965)	191,145
Total other income (expense), net	35,033,912	8,853,771
Income tax benefit (expense)	0	0
Net income	30,656,050	333,763
Preferred stock dividends	(1,129,759)	(2,517,645)
Undistributed income to Series B convertible preferred stock	(2,970,780)
Preferred stock accretion	(3,193,404)	(15,053,521)
Net income (loss) attributable to common stockholders	$ 23,362,107	$ (17,237,403)
Basic income (loss) per share attributable to common stockholders	$ 3.19	$ (1.80)
Diluted income (loss) per share attributable to common stockholders	$ 3.19	$ (1.80)
Weighted average shares outstanding basic	7,329,596	9,581,059
Weighted average shares outstanding diluted	7,329,596	9,581,059